This article is the second of two parts discussing Alexion Pharmaceuticals (ALXN) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXN’s competition. I have previously reviewed a large number of ALXN’s competitors back in October, 2017, but there have been some important developments since worth reviewing. Further, given the recent phase 3 success of ALXN1210 in paroxysmal nocturnal hemoglobinuria (PNH), and with results in atypical hemolytic uremic syndrome (aHUS) coming in Q4’18, it now becomes prudent to